Activitate de cercetare

by 3wavesblog1

Recunoașterea activității științifice (decembrie 2019)

Citări:

  • ISI (Web of Knowledge – Thomson Reuters, All databases): 1349; h-index (ISI – All databases): 16
  • ISI(Web of Knowledge – Thomson Reuters, Core Collection): 928; h-index (ISI – Core Collection): 14
  • BDI (Google Scholar): 1508; h-index: 16, i10 –index: 28

Rezultatele și valorificarea activității științifice (decembrie 2019)

  1. Articole in extenso publicate în reviste de specialitate cotate sau indexate ISI Thomson Reuters: 94
  2. Articole publicate în reviste de specialitate indexate în baze de date internaționale (BDI, PubMed, CNCSIS B+): 88
  3. Prezentări invitate în plenul unor manifestări științifice naționale: 234
  4. Prezentări invitate în plenul unor manifestări științifice internaționale: 80
  5. Studii publicate în formă de rezumat în reviste ISI Thomson Reuters: 271
  6. Studii publicate sub formă de rezumat în revistele unor manifestări științifice internaționale sau naționale cu ISBN/ISSN: 357

GRANTURI – Proiecte de cercetare internaționale și naționale

Granturi internaționale câștigate prin competiție

  1. National Coordinator for Romania, 2016 – MEDIGENE: “Genetic and environmental factors of insulin resistance syndrome and its long-term complications in immigrant Mediterranean populations FP7 Contract no. 279171”
  2. Member in the Managerial Committee (Substitute) of the Romanian Partner of COST (European Cooperation in Science and Technology) Action, BM, MoU 4159/11, entitled: “GnRH deficiency: Elucidation of the neuroendocrine control of human reproduction”, Domain: Biomedicine and Molecular Biosciences – BMBS”; interval 5th of April 2012-4th of April 2016;
  3. Person in charge for the Partner in charge: “C.I.Parhon” Endocrinology Department in the frame of Romania’s participation to the Technico-scientific cooperation contract COST Action, BM, MoU 4159/11, entitled: “GnRH deficiency: Elucidation of the neuroendocine control of human reproduction” Domain: BMBS;
  4. National Coordinator, Working Group 4, on Education and Training in Romania for COST Action, BM, MoU 4159/11. I was nominated as only representative for Romania as Invited Professor in – FENS-IBRO European Neuroscience Schools Programme, “Summer School in Neuroendocrinology” & COST – European Cooperation in Science and Technology, 2013 – University of Monasch, Prato, Italy;
  5. Coordinating Director of the Scientific Council of Consultant Experts of the International Project: “Research and Molecular, cellular and structural endocrinology laboratory” – ENDOCED, Operational Sectorial Programme “Increase of Economical Competitivity” direction 2 – cofinanced by the European Fund for Regional Development – “Investments for your future”, based on the financing contract no. 431/21.12.2012, with the National Autority for Scientific Research as an Intermediate Organism, on behalf of the Ministry of Economy, Commerce and Business Environment as a Management Authority, Project value: 45.433.476 RON, deadline: 21.06.2015;
  6. Person in charge of the scientific and technological aspects for the International Project: “Network of European Funding for Neuroscience Research” – Project number 291840, NEURON II, the 7th Framework Programme for Research and Technological Development – Frame Programme 7 of the European Committee  – FP7 ERA-NET, Budget: 42.746 Euro, Period: 01.01.2012  – 31.12.2015;
  7. Person in charge of scientific and technological aspects for the International Project: “A Definitive Roadmap for Ageing Research in Europe”, Project number: 223679, FUTURAGE, 7th Framework Programme for Research and Technological Development – Frame Programme 7 of the European Committee  – FP7 ERA-NET, Health Theme: HEALTH – 2007 – 3.4-5; Budget: 16.060 Euro, Interval: 01.09.2009 – 31.12.2011. FUTURAGE represents an important step forward in the aging research in Europe; bringing together 24 partners from 14 european countries, 8 consulting steps and over 7000 individual collaborators and organisations, representing thousands of people with the aim of creating a better future for aging in Europe. The main result of the FUTURAGE project is “The Road Map for European Ageing Research”. This aims to approach the great challenge of European population aging and sets the research agenda in the field of aging for the next decade. The document was launched within an event organised in the European Parliament on the 18th of October 2011.
  8. Person in charge of scientific and technological aspects for the International Project: ERA-AGE Extension (ERA-AGE 2), Project number: 235356, ERA-AGE 2; Frame Programme 7 of the European Committee – FP7-ERA-NET-2008 – RTD, Budget: 63451 Euro, 1.04.2009 – 30.09.2012. ERA-AGE 2 ended on the 30th of September 2012, after 3 and a half years, representing a continuation of the successful project ERA-AGE, started in 2004. During these projects 3 common calls were launched, all with Romanian participation, ending with the financing of 33 postdoctoral research projects and 6 research projects financed during the first European common call in the field of aging.
  9. Project Assistant for the International Project “The European Research Area in Ageing” – ERA-AGE – Contract ERA-NET/1/CA-SSA Nr. 510177- The European Committee Framework Six Program, Budget: 51787,98 euro; 01.03.2004-28.02.2009;
  10. Member in the research team of the International Grant ARMS 016893/2005 – The European Committee Framework Six Program (Contract nr 29/ 17.05.2007).

Granturi și proiecte de cercetare naționale câștigate prin competiție

  1. Grant Director – Project: “Skeletal and extraskeletal phenotypic particularities of the vitamin D deficiency in HIV/AIDS patients” – Theme of the competition: “Surrogate paraclinical investigations in the evaluation and treatment of the patients with osteo-renal metabolic problems” – Contract authority: European Academy of HIV/AIDS and Infectious Diseases, Financing Contract nr. 5597/12.07.2013, Grant value: 160.000 RON; Interval: 2013-2015;
  2. Member in the research team – VIASAN project entitled “Insulin resistance– major factor in the pathogenesis of the polycystic ovaries syndrome (PCOS). Role of the genes implied in insulin action. Case-control study in a Romanian PCOS population sample and healthy controls and analysis of familial cases”, Grant coordinator: Profesor Dr. M.Coculescu. Total value: 1.200.000 RON; Interval 2004-2006;
  3. Member in the research team – CNCSIS research programme financed by the state budget (A): “Case-control study of the association between calpain 10 CA, candidate gene involved in insulin resistance and polycystic ovaries syndrome”, Grant coordinator: Prof. Dr. M. Coculescu, Total value: 200.000 RON; Interval: 2007-2008;
  4. Member in the research team – CNCSIS research programme financed by the state budget (A): “Clinical and Immunohistochemical studies of the skin and mucosal determination in menopause”, Grant coordinator: Prof. Dr. Sanda Popescu; Interval: 2001-2003;
  5. Member in the research team – CNCSIS research programme B: Research base with multiple users (RBMU): “Clinical and Biological Research Center in Osteoporosis”, Grant coordinator: Prof. Dr. C. Dumitrache, Total value: 435.000 USD; Interval: 1999-2001;
  6. Member in the research team – CNCSIS research programme type D: Doctoral and Thorough Studies Programme: “Clinical, hormonal and molecular biology studies on the activity of 5 alpha reductase in androgen-dependent conditions”, Code CNCSIS: 172, Grant coordinator: Prof. Dr. C. Dumitrache, Total value: 245.000 USD, partial financing from the World Bank; Interval: 2000-2002;
  7. Member in the research team – CNCSIS research programme financed by the state budget (A): “Etiopathogenetic, evolution particularities and diagnostic and therapeutic individualisations in the endocrine neoplasia process”, Code CNCSIS: 52/409, Grant coordinator: Prof. Dr. C. Dumitrache, Total value: 250.000 RON; Interval: 1999-2001.

Membru în echipa de cercetare a 9 proiecte de cercetare științifică în cadrul Institutului Național de Endocrinologie „C. I. Parhon” – București, în colaborare cu Academia de Științe Medicale:

  1. “Evaluation of the efficacy of different therapeutic strategies used in the prophylaxis and treatment of osteoporosis” – 1999- 2001 within the HORIZON 2000 project, Code: 15.1; Title: Prevention and control of diseases with increased frequency and danger risk, UNESCO code: 3205.02 Endocrinology, Theme coordinator: Prof. Dr. C. Dumitrache;
  2. “Particularities in the diagnosis and treatment of endocrine arterial hypertension” – 1996 – 2000 within the HORIZON 2000 project, Code: 15.1; Title: Prevention and control of diseases with increased frequency and danger risk, UNESCO code: 3205.02 Endocrinology, Theme coordinator: Prof. Dr. C. Dumitrache;
  3. “Endocrine osteoporosis: etiopathogenetic forms, prophylaxis and treatment” – 1995-2000, Title: Prevention and control of diseases with increased frequency and danger risk, UNESCO code: 3205.02 Endocrinology, Theme coordinator Prof. dr. C. Dumitrache;
  4. “Individualisation of therapy in ACTH-dependent hypercortisolism” – 1992-1995, Theme coordinator: Prof. Dr. C.Dumitrache;
  5. „Longitudinal diagnostic, therapeutic and follow-up study of adrenal tumors ” – 1991-1993, Theme coordinators: Prof. Dr. C. Dumitrache, Dr. Ileana Marinescu;
  6. „Populational study of the incidence of congenital hypothyroidism by radioimmunoassay of thyroxine in dry blood from neonates in endemic and paraendemic areas ” – 1989 –1990, Theme coordinators: Dr. L. Dumitriu, Chim. Maria Oprescu;
  7. „Longitudinal study of the anti-TSH receptors antibodies involved in Basedow disease and their changes during natural history, treatment withy antithyroid medication, radioactive iodine or surgery ” – 1987-1990, Theme coordinator: Dr. L. Dumitriu;
  8. “Technico-scientific and methodological support” – 1987-1988, Theme coordinator: Dr. L. Dumitriu;
  9. „Screening research for detecting the congenital hypothyroidism by radioimmunoassay of thyroxine in dry blood „- 1986-1988, Theme coordinator: Dr. L. Dumitriu.

Studii clinice:

  1. Principal Investigator in RCT: „An open label, multicenter pasireotide roll-over protocol for patients who have completed a previous Novartis sponsored pasireotide study and are judged by the investigator to benefit from continued pasireotide treatment” – Protocol No. CSOM230B2412, 11-Mar-2016;
  2. Principal Investigator in the Clinical Trial: „A phase IIIb multicenter, open-label, single arm study to evaluate the efficacy and safety of pasireotide LAR in patients with acromegaly inadecquately controlled with first generation somatostatin analogues”, Protocol number: CSOM230C2413, 17 September 2014- June 2018;
  3. National Coordinator and Principal Investigator (Centre 02): „Retrospective study to evaluate the cost of osteoporotic fractures in the Romanian postmenopausal women population”, ORS12-0057, 2012-2013, by the National Agency for Drugs and Medical Devices, No. 29537E/ 20.08.2012;
  4. Principal Investigator in the Clinical Trial: “A Multicenter, International, Randomized, Double-Blind, Alendronate-controlled Study to Determine the Efficacy and Safety of AMG 785 (Romosozumab) in the Treatment of Postmenopausal Women with Osteoporosis” – Amgen Protocol no: 20110142, EudraCT: 2011-003142-41, Nr. IND: 100,391; ARCH: Active-contRolled FraCture Study in Postmenopausal Women With Osteoporosis at High Risk of Fracture;
  5. Principal Investigator in the Clinical Trial: SEASCAPE Study, – “An open-label, multi-center, expanded access study of pasireotide s.c. in patients with Cushing’s disease”, Protocol no: CSOM230B2406, 2011-2013;
  6. Principal Investigator in the Clinical Trial: CompliA, – “COMPLIA – A 12-month prospective, multicentre, non-interventional study to evaluate the treatment compliance and treatment satisfaction in GH deficient pediatric population treated with Nutropin AQ” – Protocol no. A-38-58035-016, 2010-2012;
  7. Principal Investigator in the Clinical Trial: “Efficacy and Long-Term Safety of Vildagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes” – CLAF237B2224, Centre Number: 0051;
  8. Principal Investigator in the Clinical Trial: ESPRIT – “Energy, Sexual desire and body proportion with Androgel, Testosterone 1% gel therapy in hypogonadal men”, multicentric, open, international study, for 6 months in 2008;
  9. Principal Investigator in the Clinical Trial, no 7153- L-02, Zavital – “A multicenter, multinational, randomized, parallel group, placebo-controlled, double blind study to evaluate efficacy and safety of a food supplement containing 80 mg soy isoflavones in the control of climacteric syndrome in postmenopausal women”- EUDRACT number: 2006-000191-32, period 2006-2007;
  10. Principal Investigator in the Clinical Trial: “European Observatioanl Study of Angeliq and other oral combined HRT (EurOSA)”, Study no 309364, Centre no 25005, period 2006-2007.